







MEDICAL DEVICE ADVERSE EVENT REPORTING FORM

Materiovigilance Programme of India

FOR MDMC/NCC USE ONLY										
Type of report: Initial Follow-up Re			Repo	eport No. :						
A. PATIENT DE	TAILS							1		
1. Patier	nt Hospital ID			Age at time of Event or Date of Birth						
2. Sex: M										
B. EVENT DETAILS										
1. Event description-										
Reason for the	E Event(Tick) a) E	lectrical	b) Mechanical	c) Electron	ic 🔲 d) Biod	compatibility	e) Clinical applica	tion error		
2. Severity of the event (Yes No if yes please specify following Required intervention to prevent death or impairment of body function Accase congenital-anomaly Life threatening Required intervention to prevent death or impairment of body function Accase of the sevent of the s										
C. MEDICAL D	EVICE(S) DETAIL									
Name of Medical Device (1)	Manufacturer (2)	Brand Name (3)	Model No. (4)	Serial No. (5)	Batch No./ Lot No. (6)	Catalogue No. (for instruments only)	Date of installation/ implantation/ explantation (8)	List of Accessories (9)		
	-					>-	* - A			
			1001					-		
	ħ.			1, 1 × 1			2-3			
10. Actions taker	n immediately after	incident	d	11. A Whether other medical devices were being used at same time with above device for therapeutic or diagnostic service? If yes, please specify						
				11 B. Any history of adverse event(s) from device with same serial/model/catalogue number. If yes please specify						
130		1								

D.REGULATORY DETAILS		134.367	E. REPORTER DETAILS of MVPI CENTRE					
Manufacturer name:	Entity legally representing	Notified Body name	TO TO					
	the Manufacture:	in:	Name and Professional Address:					
Regulator in Country of origin:	Country:	(I) Country of Manufacturing	mailE- mail Tel. No. (with STD code)					
			Designation:					
Regulatory status in origin country:		(II) In India:	Signature:dd/mni/yyyy					
F. Causality Assessment Details Completed □ In Progress □ Awaited □								
Additional Information:	9 9	7 7 7						
Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the adverse event.								



National Collaborating centre-Materiovigilance Programme of India.

Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) under the Department of Science & Technology, Government of India. Biomedical Technology Wing, Poojappura, Thrivananthapuram 695012, Kerala. Phone: 91-471 – 2340411, Fax: 91-471 -2341814, Email: head-bmtw@sctimst.ac.in.



National Coordination Centre-Materiovigilance Programme of India.

Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, Sector-23, Rajinagar, Ghaziabad-20002, Tel.:0120-2783400, 2783401, and 2783392, FAX: 0120-2783311, Email. ipclab@vsnl.net, pvpi.ipcindia@gmail.com



Technical support and Resource Centre-Materiovigilance Programme of India.

National Health System Resource Centre (NHSRC), NIHFW campus Baba Gangnath marg, Munirka, New Delhi-110067, Phones: 011 26108982 / 83 / 84 / 92 /93, Fax: 011-26108994 Email: nhsrc.india@gmail.com.

Where to report

- Duly filled Medical Device Adverse Event Reporting Form can be send to Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), National Collaboration Centre-Materiovigilance Programme of India), Biomedical Technology Wing, Poojappura, Thiruvananthapuram 695012, Kerala, India.
- > Or can directly email the duly filled form to mvpi@sctimst.ac.in.
- > Call on Helpline no. 1800 180 3024 to report Adverse event.

Event description Details of adverse event including description of device (deficiency or malfunction), clarification of hazards associated with device and the associated risk of patient, user or personany possible risk to patient associated with previous use.

Additional Information Other relevant information related to treatment should be provided.